Common in older men, often slow enough never to cause harm, and hard to screen well for exactly that reason. The variant here is one of the few reported to associate more strongly with the aggressive form than with the indolent one.
Prostate cancer is common — common enough that many men have it without knowing and die of something else. That single fact shapes everything about how it is detected and treated, because the hard question is not usually "is there cancer?" but "is this cancer one that will ever cause harm?"
rs721048 at 2p15 was identified in a genome-wide study of over 23,000 Icelanders, replicated in more than 15,500 people from Europe and the United States, with an odds ratio of 1.15.
What makes it worth a paragraph rather than a footnote: the same study reported that this variant shows a significantly stronger association with the more aggressive forms of the disease than with the less aggressive ones. Most common prostate cancer variants do not distinguish; they predict detection as much as danger. One that leans toward aggressive disease is pointing at the question that actually matters.
It is still an odds ratio of 1.15, which is nowhere near enough to guide an individual decision.
PSA testing finds cancers, including many that would never have caused symptoms. Treating those does harm — incontinence, sexual dysfunction — without benefit. Systems have responded by moving toward shared decision-making, MRI before biopsy, and active surveillance for low-risk disease rather than immediate treatment. That is why advice differs between countries and why a conversation, rather than a reflex test, is the recommendation in most of them.
Genetics does have a clinical role in prostate cancer, but not this kind: BRCA2 in particular is associated with earlier and more aggressive disease and can affect both screening discussions and treatment options. That is rare-variant, clinically-tested genetics, and it is a different subject from this page.
Know your family history — a father or brother with prostate cancer, particularly young or aggressive, is relevant and worth telling your doctor. Take urinary symptoms, bone pain or blood in the urine to a clinician. And if you are weighing up PSA testing, that decision deserves an actual conversation about what a result would and would not mean.
rs721048 (2p15). Identified in a genome-wide SNP association study of over 23,000 Icelanders with replication in over 15,500 individuals from Europe and the United States; OR 1.15, P = 7.7 x 10-9. The same study reported rs5945572 on Xp11.22 (OR 1.23, P = 3.9 x 10-13). The 2p15 variant showed a significantly stronger association with more aggressive than with less aggressive disease — notable because differentiating indolent from consequential disease is the central problem in prostate cancer, and most common variants do not.
Common versus rare. More than a hundred common susceptibility loci are known and polygenic scores have been evaluated for risk stratification, including for targeted screening; they are not standard practice. Separately, germline BRCA2 and to a lesser extent BRCA1, ATM, CHEK2 and mismatch repair genes are associated with earlier onset and more aggressive disease, influence screening discussions in affected families, and — for BRCA2 and other homologous recombination repair defects — affect eligibility for PARP inhibitor therapy in advanced disease. That is the genetics that changes management.
Screening. PSA-based screening reduces prostate cancer mortality modestly at the cost of substantial overdiagnosis; guidelines therefore emphasise informed decision-making, and practice has shifted toward pre-biopsy MRI and active surveillance for low-risk disease. Risk stratification uses PSA, examination, imaging, biopsy grade group and stage; no common variant enters that assessment.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Prostate Cancer comes down to these specific, well-studied positions — not a diagnosis.
No. An odds ratio of 1.15 does not shift that decision, which turns on age, family history, ancestry and your own view of the trade-off between finding cancers early and treating ones that would never have harmed you.
That the association was significantly stronger for aggressive than for indolent tumours in the study that found it. That is unusual and scientifically interesting, because separating dangerous from harmless prostate cancer is the central difficulty. It is still far too small an effect to act on.
Yes. BRCA2 in particular is associated with earlier and more aggressive prostate cancer, can change screening conversations in affected families, and affects treatment options in advanced disease. That is rare-variant clinical testing, not what this page describes.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.